CBD (cannabidiol) and CBD-rich extracts may provide a potential treatment option for endometrial cancer, according to a new study published by the Journal of Physiology and Biochemistry, and published online by the U.S. National Institute of Health.
“Among a variety of phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most promising therapeutic compounds”, begins the study’s abstract. “Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of tumor cells. Likewise, the major endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), induce tumor cell death.”
The purpose of the present study “was to characterize cannabinoid elements and evaluate the effect of cannabinoids in endometrial cancer cell viability.” Endometrial cancer is a variety of cancer that begins in the lining of the uterus.
After conducted a series of tests, researchers found that “these data indicate that cannabinoids modulate endometrial cancer cell death. Selective targeting of TPRV1 by AEA, CBD, or other stable analogues may be an attractive research area for the treatment of estrogen-dependent endometrial carcinoma.”
They conclude by stating that; “Our data further support the evaluation of CBD and CBD-rich extracts for the potential treatment of endometrial cancer, particularly, that has become non-responsive to common therapies.”
The full study, conducted by researchers at the Universidade do Porto in Portugal, can be found by clicking here.